Protalix BioTherapeutics, Inc. (DE) (PLX) News
Filter PLX News Items
PLX News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
PLX News Highlights
- PLX's 30 day story count now stands at 2.
- Over the past 26 days, the trend for PLX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PLX are LEVI and NOV.
Latest PLX News From Around the Web
Below are the latest news stories about PROTALIX BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate PLX as an investment opportunity.
Protalix BioTherapeutics Issues 2024 Letter to StockholdersProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. |
Levicept Appoints Eliot Forster as CEOLeadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty y |
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript November 6, 2023 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Good morning, ladies and gentlemen. And welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I […] |
PLX: More Regulatory ApprovalsBy John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2023 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 3Q:23 financial and operational results in a November 6th, 2023 press release and filing of Form 10-Q . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial |
Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial ResultsProtalix BioTherapeutics Inc (PLX) reported a net income of $14.36 million for Q3 2023, a significant improvement from a loss of $11.19 million in the same period last year. The company's cash and cash equivalents increased to $20.41 million from $17.11 million at the end of 2022. Protalix continues to advance its clinical trial of PRX-115, a potential treatment for severe gout, with top-line results expected in mid-2024. |
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business ResultsProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the third quarter ended September 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments. |
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023. |
Protalix BioTherapeutics Issues Statement Regarding Security Situation in IsraelProtalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today issued the following statement by Dror Bashan, Protalix's President and Chief Executive Officer, regarding the current security situation in Israel. |
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of DirectorsAppointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors |
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, September 13, 2023 at 3:00 p.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 25th Annual Global Investment Conference. |